Atlas Venture Fund XI, L.P. bought $1.1M of SION
owner at Sionna Therapeutics, Inc.. 60,000 shares at an average of $18.00, traded Feb 10, 2025, filed Feb 10, 2025.
Score components
- +12Role10% owner
- +25Trade size$1.1M at market
- +3Relative to holdingsHoldings up 8%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -23.1%, 3m -42.0%, 6m -9.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-017030, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 10, 2025 | CConversion Common Stock | +2,886,293 | - | - | 2,886,293 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P. | +747,727 | - | - | 747,727 | Feb 10, 2025 |
| Feb 10, 2025 | POpen-market purchase Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P. | +60,000 | $18.00 | $1.1M | 807,727 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series Seed convertible preferred stockderivative | -1,051,051 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series A convertible preferred stockderivative | -1,806,317 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series B convertible preferred stockderivative | -1,298,332 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series C convertible preferred stockderivative | -61,463 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series C convertible preferred stockderivativeindirect: By Atlas Venture Opportunity Fund II, L.P. | -1,092,504 | $0.00 | $0 | 0 | Feb 10, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $3.9M 85,918 shares | -3% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $3.9M 85,918 shares | -3% | |
| 32Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $447k 10,250 shares | -100% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $5.3M 115,844 shares | -4% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $5.3M 115,844 shares | -4% | |
| 3Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $4,493 101 shares | -0% | |
| 3Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $4,493 101 shares | -0% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $13M 292,952 shares | -10% | |
| 28Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $13M 292,952 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.